UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000042571
Receipt number R000048591
Scientific Title Effects of Flail Prophylaxis Interventions by The Health Support Pharmacy Pharmacists on aged Chronic Disease Patients : a Practical Cluster Randomized Trial
Date of disclosure of the study information 2021/01/01
Last modified on 2021/11/29 08:17:05

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Intervention study by pharmacy pharmacist to prevent flail

Acronym

Pharmacy flail study

Scientific Title

Effects of Flail Prophylaxis Interventions by The Health Support Pharmacy Pharmacists on aged Chronic Disease Patients : a Practical Cluster Randomized Trial

Scientific Title:Acronym

FHSP Trial

Region

Japan


Condition

Condition

Flail

Classification by specialty

Medicine in general

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

This time, for patients with chronic diseases aged 75 to 79 who use the health support pharmacy operated by Osaka Pharmaplan, the pharmacy pharmacist will provide information on frailty prevention measures at the time of medication instruction, so that the patients can Encourage daily exercise and try to verify whether it increases muscle mass.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2

Pragmatic

Developmental phase

Not applicable


Assessment

Primary outcomes

The amount of change(Kg) and the rate of change(%) of "muscle mass by site" measured with a body composition analyzer after 6 months. The rate of change(%) after 6 months of the "5 times chair stand-up test".

Key secondary outcomes

The amount and rate of change of "body weight," "body fat percentage," "BMI," and "estimated bone mass" measured with a body composition analyzer after 6 months. Comparison between groups of the results of the "health status questionnaire" that was first surveyed and comparison of the amount of change in body composition. Evaluation of the results of the "retrospective questionnaire" surveyed 6 months later.


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Cluster

Blinding

Open -no one is blinded

Control

No treatment

Stratification

YES

Dynamic allocation

NO

Institution consideration

Institution is considered as a block.

Blocking

YES

Concealment

Pseudo-randomization


Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Behavior,custom

Interventions/Control_1

At the time of medication instruction, you will be given a leaflet of "Exercise to prevent flail at home" (Attachment 4) to prevent flail, and encourage daily exercise and exercise to prevent flail. At the time of the 2nd to 5th visits to the station, we will give you the flail prevention exercise leaflet that you gave at the first time, confirm that you are exercising, and encourage you to exercise and exercise for flail prevention again. If you have time, perform a "five chair stand-up test" and record it. After the 6th visit (final) medication instruction, measure "muscle mass", "weight", "body fat percentage", "BMI", "estimated bone mass", and "5th chair standing test" with a body composition analyzer, and "record" Record on "paper". Finally, please complete the "Reflection Questionnaire".

Interventions/Control_2

At the time of the 1st to 5th visits. Give normal medication guidance. At that time, check whether you are exercising every day. At the 6th visit. After taking the medicine, measure "muscle mass", "weight", "body fat percentage", "BMI", "estimated bone mass", and "5 times chair standing test" with a body composition analyzer and record them on a recording sheet. We will give you a leaflet of "Exercise for flail prevention that you can do at home" to encourage awareness and exercise for flail prevention. Please answer the "Reflection Questionnaire" and finish it once.

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

75 years-old <=

Age-upper limit

79 years-old >=

Gender

Male and Female

Key inclusion criteria

Of the 12 pharmacies operated by Osaka Pharma Plan, 10 pharmacies that meet the standards of health support pharmacies (Aozora Pharmacy, Aozora Pharmacy Awaji Store, Aoba Pharmacy, Kagayaki Pharmacy, Kotsuma Pharmacy, Sumire Pharmacy, Soyokaze Pharmacy, Nagisa Pharmacy, Natsume Pharmacy, Moegi Pharmacy), among the patients who come to the pharmacy to receive prescription dispensing every month, are prescribed for chronic diseases (hypertension, diabetes, dyslipidemia, etc.) 75 years old to 79 years old Among the following patients, those who consented to this study are the target patients.

Key exclusion criteria

Patients who are undergoing treatment that may affect physical malnutrition or bones, such as cancer patients. Patients who are prescribed an osteoporosis drug. Patients who are prescribed antidepressants or antipsychotics. Patients who are prescribed steroids. Patients who are prescribed dementia medication. Obese patients with a BMI of 30% or higher. Patients receiving exercise restriction guidance from their doctor.

Target sample size

120


Research contact person

Name of lead principal investigator

1st name Noritake
Middle name Noritake
Last name Hirota

Organization

General Incorporated Association Osaka Pharmaplan

Division name

Aozora Pharmacy

Zip code

5550024

Address

3-6-8, Nozato, Nishiyodogawa-ku, Osaka city, Japan

TEL

0664778088

Email

n-hirota@faruma.co.jp


Public contact

Name of contact person

1st name Noritake
Middle name
Last name Hirota

Organization

General Incorporated Association Osaka Pharmaplan

Division name

Aozora Pharmacy

Zip code

555-0024

Address

3-6-8, Nozato, Nishiyodogawa-ku, Osaka city, Japan

TEL

0664778088

Homepage URL


Email

n-hirota@faruma.co.jp


Sponsor or person

Institute

General Incorporated Association Osaka Pharmaplan Aozora Pharmacy

Institute

Department

Personal name



Funding Source

Organization

General Incorporated Association Osaka Pharmaplan Aozora Pharmacy

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

General Incorporated Association Osaka Pharmaplan Aozora Pharmacy

Address

3-6-8, Nozato, Nishiyodogawa-ku, Osaka city, Japan

Tel

0664778088

Email

n-hirota@faruma.co.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

あおぞら薬局(大阪府)、あおぞら薬局淡路店(大阪府)、あおば薬局(大阪府)、かがや薬局(大阪府)、こつま薬局(大阪府)、すみれ薬局(大阪府)、そよかぜ薬局(大阪府)、なぎさ薬局(大阪府)、なつめ薬局(大阪府)、もえぎ薬局(大阪府)


Other administrative information

Date of disclosure of the study information

2021 Year 01 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2020 Year 09 Month 01 Day

Date of IRB

2010 Year 11 Month 05 Day

Anticipated trial start date

2020 Year 12 Month 01 Day

Last follow-up date

2021 Year 08 Month 31 Day

Date of closure to data entry

2021 Year 09 Month 30 Day

Date trial data considered complete

2021 Year 09 Month 30 Day

Date analysis concluded

2021 Year 11 Month 28 Day


Other

Other related information



Management information

Registered date

2020 Year 11 Month 27 Day

Last modified on

2021 Year 11 Month 29 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000048591


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name